ClinicalTrials.gg

Program

pemafibrate

Also written as “K-877”, “K-877 0.1 mg tablet” and “K-808 (Dose A)”.

Its studies are mostly in Liver Cirrhosis, Biliary · Hypercholesterolemia · Dyslipidemias · Hyperlipidemias · Non-alcoholic Fatty Liver Disease, led by Kowa.

Furthest: phase 4, since Jun 4, 202617 company-led studies, 1 open or runningNext primary completion: Jul 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kowa171 open or runningphase 4since Jun 4, 2026Oct 22, 2014Jul 31, 2027phase 4 · NCT07634484

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 22, 2014First studies: 5 phase 1 studies in HealthyFirst studyNCT02273986, NCT02276001, NCT02275988 and 2 more
  2. Jan 29, 2016Phase 1 study in HealthyNCT02719431 · 20 enrolled · United States
  3. Sep 15, 2016Phase 1 study in HealthyNCT02922465 · 20 enrolled · United States
  4. Feb 23, 2017Phase 3 study in DyslipidemiasNCT03071692 · 10,544 enrolled · United States, Argentina, Brazil and more
  5. Nov 9, 2017Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT03350165 · 118 enrolled · Japan
  6. Sep 3, 2019Phase 2 study in DyslipidemiasNCT04079530 · 60 enrolled · Japan
  7. Jan 16, 2020Phase 1 study in HealthyNCT04237597 · 20 enrolled · United States
  8. Jan 29, 2021Phase 1 study in HealthyNCT04742218 · 18 enrolled · United States
  9. Jul 14, 2021Phase 3 study in HyperlipidemiasNCT04998981 · 353 enrolled · China
  10. Jun 20, 2023Phase 3 study in HypercholesterolemiaNCT05923281 · 71 enrolled · Japan
  11. Jan 22, 2024Phase 2 study in Liver Cirrhosis, BiliaryNCT06247735 · 46 enrolled · United States, Canada, Japan
  12. Jun 27, 2024Phase 1 study in Liver Cirrhosis, BiliaryNCT06525311 · 17 enrolled · United States, Japan
  13. Jun 4, 2026Phase 4 study in HypercholesterolemiaNCT07634484 · 120 planned · Japan

Ahead

  1. Jul 31, 2027Primary completion: phase 4 study in HypercholesterolemiaNCT07634484

TargetBeta

PPARA →read by rule
“Peroxisome proliferator-activated receptor alpha agonist”ChEMBL 37, by rule

Other programs on PPARA

ProgramCompanyFurthest phaseStudies
saroglitazarruleZydus Lifesciencesphase 419
elifibranorruleGenfitphase 324
seladelparruleGilead Sciencesphase 314
chiglitazarruleChipscreen Biosciencesphase 39
Gemfibrozilrulepolaryx-therapeutics-incphase 38
lanifibranorinventiva-pharmaphase 36

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07634484Hypercholesterolemia · Japan4RecruitingJul 31, 2027120
NCT06525311Liver Cirrhosis, Biliary · United States, Japan1CompletedMar 12, 202517
NCT06247735Liver Cirrhosis, Biliary · United States, Canada, Japan2CompletedJun 26, 202546
NCT05923281Hypercholesterolemia · Japan3CompletedAug 7, 202471
NCT04998981Hyperlipidemias · China3CompletedFeb 2, 2023353
NCT04742218Healthy · United States1CompletedApr 11, 202118
NCT04237597Healthy · United States1CompletedJan 31, 202020
NCT04079530Dyslipidemias · Japan2CompletedDec 24, 201960
NCT03350165Non-alcoholic Fatty Liver Disease · Japan2CompletedApr 3, 2019118
NCT03071692Dyslipidemias · United States, Argentina, Brazil and more3TerminatedJul 27, 202210,544
NCT02922465Healthy · United States1CompletedOct 201620
NCT02719431Healthy · United States1CompletedFeb 201620
NCT02276001Healthy · United States1CompletedJul 201420
NCT02275988Healthy · United States1CompletedAug 201420
NCT02275975Healthy · United States1CompletedAug 201420
NCT02275962Healthy · United States1CompletedOct 201420
NCT02273986Healthy · United States1CompletedSep 201420

How it is read

Names in the registry

  • “K-877”, 11 entries
  • “K-877 0.1 mg tablet”, 2 entries
  • “K-808 (Dose A)”, 1 entry
  • “K-808 (Dose B)”, 1 entry
  • “Pemafibrate 0.2 mg/day”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.